<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425929</url>
  </required_header>
  <id_info>
    <org_study_id>PROXY</org_study_id>
    <nct_id>NCT03425929</nct_id>
  </id_info>
  <brief_title>Oxytocin, Trauma Disclosure and Intrusions</brief_title>
  <official_title>Effects of a Prolonged Oxytocin Treatment on Intrusions and Amygdala Reactivity in an Analogue Trauma Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe traumatic experiences such as falling victim to assault, torture, or rape have
      deleterious effects. Clinical manifestations include intrusions, avoidance behavior, and
      hyperarousal, which are associated, at a circuit level, with hyperfunction of the amygdala
      and hypofunction of prefrontal cortex (PFC) subregions. In up to 50 % of the cases,
      resilience is not sufficient and trauma-exposed individuals develop posttraumatic stress
      disorder (PTSD). Oxytocin (OXT) is a hypothalamic peptide hormone that exerts anxiolytic
      effects. Recent clinical trials provide preliminary evidence that post-trauma administration
      of OXT could be effective as a preventive intervention for PTSD in a subsample of individuals
      exhibiting early PTSD symptoms prior to the onset of the disorder. However, the underlying
      neurobiological mechanisms are unclear. Therefore, the rationale of the present project is to
      expose a sample of healthy participants to experimental trauma in order to explore the
      circuit mechanisms by which OXT influences, and interferes with, traumatic experience.
      Functional magnetic resonance imaging (fMRI) will be employed in order to elucidate the
      long-term effects of intranasal OXT on trauma-induced intrusions, amygdala and PFC responses
      during an emotional face matching task and resting state functional connectivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be exposed to an experimental trauma (i.e. a highly aversive movie) at days
      1 and 4 of the study. After the first experimental trauma and after the first functional
      magnetic resonance imaging (fMRI) measurement, the participants will receive intranasal OXT
      or placebo in three different groups (1. OXT for six days, 2. OXT for three days and then
      placebo for three days, 3. placebo for six days). The same fMRI tasks will be used after the
      first and second trauma exposure (i.e. one measurement before the treatment and one
      measurement after three days of treatment).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">March 18, 2017</completion_date>
  <primary_completion_date type="Actual">March 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of intrusions following the first trauma movie exposure.</measure>
    <time_frame>Three days following the first trauma movie exposure.</time_frame>
    <description>The participants will be asked to complete intrusion diaries at home in the evening of the days 1 to 3. Intrusions will be defined as involuntary recollections relating to film events that appear, apparently spontaneously, in consciousness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total number of intrusions following the second trauma movie exposure.</measure>
    <time_frame>Three days following the second trauma movie exposure.</time_frame>
    <description>The participants will be asked to complete intrusion diaries at home in the evening of the days 4 to 6. Intrusions will be defined as involuntary recollections relating to film events that appear, apparently spontaneously, in consciousness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural responses to emotional faces in the amygdala.</measure>
    <time_frame>Neural activations will be measured with fMRI in an emotional face matching task that lasts 20 min.</time_frame>
    <description>Functional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate amygdala responses to emotional faces, because pilot data indicate that neural responses to emotional faces in these regions are associated with the total number of intrusions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural responses to emotional faces in the prefrontal cortex.</measure>
    <time_frame>Neural activations will be measured with fMRI in an emotional face matching task that lasts 20 min.</time_frame>
    <description>Functional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate prefrontal cortex responses to emotional faces, because pilot data indicate that neural responses to emotional faces in these regions are associated with the total number of intrusions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI resting state data</measure>
    <time_frame>Functional data will be acquired for 6 min.</time_frame>
    <description>Participants will be instructed to lie still with open eyes during the resting state measurement and not think of anything in particular.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trauma disclosure (time spend discussing the movie)</measure>
    <time_frame>Six days following the first trauma movie exposure.</time_frame>
    <description>The intrusion diaries will contain a question for how long participants discussed the trauma movie.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in pupil diameter in response to the trauma movie</measure>
    <time_frame>2 min baseline before the trauma movie and during 15 min of the trauma movie.</time_frame>
    <description>Changes in pupil diameter will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in skin conductance level in response to the trauma movie</measure>
    <time_frame>2 min baseline before the trauma movie and during 15 min of the trauma movie.</time_frame>
    <description>Changes in skin conductance level will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in respiration rate in response to the trauma movie</measure>
    <time_frame>2 min baseline before the trauma movie and during 15 min of the trauma movie.</time_frame>
    <description>Changes in respiration rate will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary oxytocin concentrations</measure>
    <time_frame>Immediately before the trauma movie, immediately after the trauma movie and 40 min after the trauma movie.</time_frame>
    <description>Saliva samples will be collected before and after the trauma movie to assess changes in oxytocin concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary cortisol concentrations</measure>
    <time_frame>Immediately before the trauma movie, immediately after the trauma movie and 40 min after the trauma movie.</time_frame>
    <description>Saliva samples will be collected before and after the trauma movie to assess changes in cortisol concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire measurement of mood (PANAS)</measure>
    <time_frame>10 min before and 10 min after the trauma movie.</time_frame>
    <description>Positive and negative affect will be assessed via self-rating questionnaire 'The Positive and Negative Affect Schedule' using a categorical 5 point scale.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oxytocin (6 days)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure and three days after the second trauma movie exposure (24 IU per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin (3 days)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure (24 IU per day) and placebo nasal spray for three days after the second trauma movie exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray for six days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Intranasal administration, 24 international units (IU) oxytocin.</description>
    <arm_group_label>Oxytocin (6 days)</arm_group_label>
    <arm_group_label>Oxytocin (3 days)</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo nasal sprays contain identical ingredients except for the peptide itself.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female volunteers

          -  Right-handed

        Exclusion Criteria:

          -  Current or past psychiatric disease

          -  Current or past physical illness

          -  Psychoactive medication

          -  Hormonal contraception

          -  MRI contraindication (e.g. metal in body, claustrophobia)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ren√© Hurlemann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://renehurlemann.squarespace.com/welcome/</url>
    <description>Neuromodulation of Emotion (NEMO) research group</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Rene Hurlemann</investigator_full_name>
    <investigator_title>Vice Chair of the Department of Psychiatry and Chair of the Medical Psychology Division</investigator_title>
  </responsible_party>
  <keyword>amygdala, fear, intrusion, oxytocin, trauma disclosure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

